Cardiff Oncology to Advance Onvansertib to First-Line mCRC, Partners with Pfizer Ignite for New Trial

Cardiff Oncology, Inc.

Announces new lead program in first-line RAS-mutated metastatic colorectal cancer with FDA agreement.
Launches CRDF-004 Phase 2 trial with 90 patients; interim topline results expected mid-2024.
Pfizer Ignite will support clinical execution; expands relationship from Pfizer's 2021 equity investment.
Discontinues ONSEMBLE second-line trial to focus resources on first-line program.
Cash position of $89.4M as of June 30, 2023, sufficient to fund operations into 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.